利奈唑胺个体化给药研究进展

Abstract
Figure/Table
References (23)
Related Citation (6)

Download: PDF (723 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Due to Vancomycin resistance and adverse reactions, Linezolid has become increasingly important in the treatment of infections caused by Methicillin-Resistant Staphylococcus Aureus and other multi-resistant and pan-resistant bacteria. However, research on how Linezolid can be personalized medicine is still insufficient. Studies have shown that the pharmacokinetics of Linezolid are affected by various factors such as age, gender, weight, liver and kidney function, and genes, which can lead to individual differences in efficacy and adverse reactions. Many studies have confirmed the role of therapeutic drug monitoring in the individualized administration of linezolid, but its application value remains to be further confirmed. Pharmacokinetics/pharmacodynamics studies have shown that individualized dosing regimens should be designed based on the patient′s disease status and drug sensitivity results. Therefore, clinical pharmacists should use therapeutic drug monitoring and pharmacokinetics/pharmacodynamics actively participate in clinical treatment to improve the effectiveness and safety of Linezolid anti-infective treatment.

Key words： Linezolid Pharmacokinetics Pharmacodynamics Therapeutic drug monitoring Individualized administration

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Dong1 KONG Lingti2 XU Haiyan1

Cite this article:

LIU Dong1 KONG Lingti2 XU Haiyan1. Progress on individualized administration of Linezolid[J]. 中国医药导报, 2020, 17(26): 34-36,48.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I26/34

[1] Cao B，Tan TT，Poon E，et al. Consensus statement on the management of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Asia [J]. Clin Respir J，2015，9（2）：129-142.
[2] Carreno JJ，Kenney RM，Divine G，et al. Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes （STOP-NT）[J]. Ann Pharmacother，2017，51（3）：185-193.
[3] Fernández-Barat L，Motos A，Panigada M，et al. Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients [J]. Crit Care，2019， 23（1）：251.
[4] 桑德福.热病：桑德福抗微生物治疗指南[M].范洪伟，译.48版.北京：中国协和医科大学出版社，2019.
[5] 辉瑞制药.利奈唑胺葡萄糖注射液说明书[EB/OL].http://dayi.org.cn/drug/1152166?from=sll.
[6] 王国建，陈建.临床治疗中利奈唑胺的药效学和药动学研究进展[J].中国抗生素杂志，2013，38（10）：730-735.
[7] Sisson LT，Jungbluth GL，Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid [J]. Eur J Clin Pharmacol，2002，57（11）：793-797.
[8] Xie F，Mantzarlis K，Malliotakis P，et al. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia [J]. J Antimicrob Chemother，2019，74（3）：667-674.
[9] Minichmayr IK，Schaeftlein A，Kuti JL，et al. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid：a pooled population pharmacokinetic analysis with focus on critically ill patients [J]. Clin Pharmacokinet，2017，56（6）：617-633.
[10] Wicha SG，Frey OR，Roehr AC，et al. Linezolid in liver failure：exploring the value of the maximal liver function capacity（LiMAx）test in a pharmacokinetic pilot study [J]. Int J Antimicrob Agents，2017，50（4）：557-563.
[11] Allegra S，Di Paolo A，Cusato J，et al. A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance [J]. Ther Drug Monit，2018，40（5）：602-609.
[12] Xiao ZR，Yin GL，Ni Y，et al. MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients [J]. Biomed Pharmacother，2017，95：743-748.
[13] 张相林，缪丽燕，陈文倩.治疗药物监测工作规范专家共识（2019版）[J].中国医院用药评价与分析，2019，19（8）：897-898，902.
[14] Cattaneo D，Gervasoni C，Cozzi V，et al. Therapeutic drug management of linezolid：a missed opportunity for clinicians? [J]. Int J Antimicrob Agents，2016，48（6）：728-731.
[15] Cojutti PG，Merelli M，Bassetti M，et al. Proactive therapeutic drug monitoring（TDM）may be helpful in managing long-term treatment with linezolid safely：findings from a monocentric，prospective，open-label，interventional study [J]. J Antimicrob Chemother，2019，74（12）：3588-3595.
[16] Galar A，Valerio M，Munoz P，et al. Systematic therapeutic drugmonitoring for linezolid：variability and clinical impact [J]. Antimicrob Agents Chemother，2017，61（10）：e00687-17.
[17] Pea F，Cojutti P，Dose L，et al. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing：one stone for two birds? [J]. Br J Clin Pharmacol，2016，81（2）：341-348.
[18] Pea F，Cojutti PG，Baraldo M. A 10-Year Experience of Therapeutic Drug Monitoring（TDM）of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing：Is there Enough Evidence for Suggesting TDM in the Majority of Patients? [J]. Basic Clin Pharmacol Toxicol，2017，121（4）：303-308.
[19] 中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志，2018，41（6）：409-446.
[20] Cai Y，Bai N，Liu X，et al. Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers [J]. Int J Clin Pharmacol Ther，2015，53（9）：765-771.
[21] Yang MJ，Zhang J，Chen YC，et al. Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/ pharmacodynamic analysis [J]. Future Microbiol，2017，12：39-50.
[22] Dong HY，Xie J，Wang TT，et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients [J]. Int J Antimicrob Agents，2016，48（3）：259-264.
[23] Rao GG，Konicki R，Cattaneo D，et al. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice：A Review of Linezolid Pharmacokinetics and Pharmacodynamics [J]. Ther Drug Monit，2020，42（1）：83-92.